The introduction of sodium-glucose cotransporter 2 (SGLT2) inhibitors as a new and
effective class of therapeutic agents for type 2 diabetes (T2D) preventing the reabsorption of …

Objective Cardiovascular (CV) outcome trials have shown that in patients with type 2
diabetes (T2D), treatment with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduces …

The recently published randomized trials (RCTs) evaluating the effect of Sodium-glucose
cotransporter-2 inhibitors (SGLT2i) in heart failure with mildly reduced (HFmrEF) or …

Background Nearly half of patients with heart failure (HF) have preserved ejection fraction
(EF) and the mortality and morbidity of patients with HF with preserved EF (HFpEF) are high …

Background The rising concern of irreproducible and non-transparent studies poses a
significant challenge in modern medical literature. The impact of this issue on cardiology …

Kalp yetersizliği (KY), yeni yayınlanan KY kılavuzlarınca düşük ejeksiyon fraksiyonlu (DEF-
KY), hafif azalmış ejeksiyon fraksiyonlu (HEF-KY) ve korunmuş ejeksiyon fraksiyonlu (KEF …

About 10 million people in Indonesia have been impacted by heart failure (HF), which is a
complex clinical syndrome caused by insufficient cardiac output that is unable to meet the …

In this issue of the Journal, Roberto Pontremoli and his coauthors propose a practical
approach for the prescription of SGLT2 inhibitors (SGLT2i) in patients with heart failure [1] …

Over the last six decades, treatment intervention for HFpEF, especially in diabetic patients,
has presented a clinical conundrum in the healthcare population. According to studies, more …

Background: The rising concern of irreproducible and non-transparent studies poses a
significant challenge in modern medical literature. The impact of this issue on cardiology …